51
|
Feng H, Dong Y, Wu J, Qiao Y, Zhu G, Jin H, Cui J, Li W, Liu YJ, Chen J, Song Y. Epirubicin pretreatment enhances NK cell-mediated cytotoxicity against breast cancer cells in vitro. Am J Transl Res 2016; 8:473-484. [PMID: 27158340 PMCID: PMC4846897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Accepted: 12/24/2015] [Indexed: 06/05/2023]
Abstract
Anthracycline-based chemotherapy is a conventional treatment for breast cancer. However, it can negatively affect host immune function and thereby impair patients' quality of life. Boosting the host immune system and reducing the adverse effect of chemotherapy are important for effective cancer treatment. Natural killer (NK) cells stimulate immune responses against cancer; autologous immune enhancement therapy with NK cells prolongs patient survival without significant adverse effects. This study investigated the effects of combined treatment with the anthracycline agent epirubicin (EPI) and NK cells on human breast cancer cells. NK cells were obtained by autologous adoptive cell transfer from breast cancer patients and amplified for 14 days in vitro. The cytotoxicity of NK cells against breast cancer cells was higher following EPI (5.0 μg/ml) pretreatment than without EPI pretreatment or application of EPI alone. The expression of NKG2D ligands [unique long 16-binding protein (ULBP) 1, ULBP2, and major histocompatibility complex class I-related chain A] in breast cancer cells was upregulated by pretreatment with EPI, which also increased the secretion of interferon-γ and tumor necrosis factor-α and expression of perforin and granzyme B in NK cells. These results indicate that EPI-NK cell treatment has synergistic cytotoxic effects against breast cancer cells, and suggest that anthracycline-based chemotherapy and NK cell-based immunotherapy can be combined for more effective breast cancer treatment.
Collapse
Affiliation(s)
- Hui Feng
- Cancer Center, The First Hospital of Jilin UniversityChangchun 130031, China
| | - Ying Dong
- Cancer Center, The First Hospital of Jilin UniversityChangchun 130031, China
| | - Jing Wu
- Institute of Translational Medicine, The First Hospital of Jilin UniversityChangchun 130031, China
| | - Yuan Qiao
- Institute of Translational Medicine, The First Hospital of Jilin UniversityChangchun 130031, China
| | - Ge Zhu
- Cancer Center, The First Hospital of Jilin UniversityChangchun 130031, China
| | - Haofan Jin
- Cancer Center, The First Hospital of Jilin UniversityChangchun 130031, China
| | - Jiuwei Cui
- Cancer Center, The First Hospital of Jilin UniversityChangchun 130031, China
| | - Wei Li
- Cancer Center, The First Hospital of Jilin UniversityChangchun 130031, China
| | - Yong-Jun Liu
- Institute of Translational Medicine, The First Hospital of Jilin UniversityChangchun 130031, China
- MedImmuneGaithersburg, MD 20878, USA
| | - Jingtao Chen
- Cancer Center, The First Hospital of Jilin UniversityChangchun 130031, China
- Institute of Translational Medicine, The First Hospital of Jilin UniversityChangchun 130031, China
| | - Yanqiu Song
- Cancer Center, The First Hospital of Jilin UniversityChangchun 130031, China
| |
Collapse
|
52
|
Ishii K, Barrett AJ. Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). Ther Adv Hematol 2016; 7:17-39. [PMID: 26834952 PMCID: PMC4713888 DOI: 10.1177/2040620715616544] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
There have been major advances in our understanding of the multiple interactions between malignant cells and the innate and adaptive immune system. While the attention of immunologists has hitherto focused on solid tumors, the specific immunobiology of acute leukemias is now becoming defined. These discoveries have pointed the way to immune interventions building on the established graft-versus-leukemia (GVL) effect from hematopoietic stem-cell transplant (HSCT) and extending immunotherapy beyond HSCT to individuals with acute leukemia with a diversity of immune manipulations early in the course of the leukemia. At present, clinical results are in their infancy. In the coming years larger studies will better define the place of immunotherapy in the management of acute leukemias and lead to treatment approaches that combine conventional chemotherapy, immunotherapy and HSCT to achieve durable cures.
Collapse
Affiliation(s)
- Kazusa Ishii
- Hematology Branch, National Heart, Lung, and Blood Institute, US National Institutes of Health, Bethesda, MD, USA
| | - Austin J. Barrett
- Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
53
|
Tarazona R, Duran E, Solana R. Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy. Front Immunol 2016; 6:649. [PMID: 26779186 PMCID: PMC4703774 DOI: 10.3389/fimmu.2015.00649] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Accepted: 12/14/2015] [Indexed: 11/13/2022] Open
Abstract
Natural killer (NK) cells participate in the early immune response against melanoma and also contribute to the development of an adequate adaptive immune response by their crosstalk with dendritic cells and cytokine secretion. Melanoma resistance to conventional therapies together with its high immunogenicity justifies the development of novel therapies aimed to stimulate effective immune responses against melanoma. However, melanoma cells frequently escape to CD8 T cell recognition by the down-regulation of major histocompatibility complex (MHC) class I molecules. In this scenario, NK cells emerge as potential candidates for melanoma immunotherapy due to their capacity to recognize and destroy melanoma cells expressing low levels of MHC class I molecules. In addition, the possibility to combine immune checkpoint blockade with other NK cell potentiating strategies (e.g., cytokine induction of activating receptors) has opened new perspectives in the potential use of adoptive NK cell-based immunotherapy in melanoma.
Collapse
Affiliation(s)
- Raquel Tarazona
- Immunology Unit, University of Extremadura , Caceres , Spain
| | - Esther Duran
- Histology and Pathology Unit, Faculty of Veterinary Medicine, University of Extremadura , Caceres , Spain
| | - Rafael Solana
- Immunology Unit, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba , Cordoba , Spain
| |
Collapse
|
54
|
Kim HS. A multifaceted approach targeting NK cells for better treatment of cancer: focus on hematological malignancies. Blood Res 2015; 50:189-91. [PMID: 26770944 PMCID: PMC4705042 DOI: 10.5045/br.2015.50.4.189] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Affiliation(s)
- Hun Sik Kim
- Department of Biomedical Sciences, University of Ulsan College of Medicine, Seoul, Korea.; Department of Microbiology, University of Ulsan College of Medicine, Seoul, Korea
| |
Collapse
|
55
|
Liu LL, Pfefferle A, Yi Sheng VO, Björklund AT, Béziat V, Goodridge JP, Malmberg KJ. Harnessing adaptive natural killer cells in cancer immunotherapy. Mol Oncol 2015; 9:1904-17. [PMID: 26604011 PMCID: PMC5528731 DOI: 10.1016/j.molonc.2015.10.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2015] [Revised: 09/28/2015] [Accepted: 10/04/2015] [Indexed: 12/17/2022] Open
Abstract
Natural killer (NK) cells are innate lymphocytes with a refined ability to recognize transformed cells through a broad array of activating receptors in combination with stochastically expressed inhibitory receptors that recognize MHC-class I. Recent advances in NK cell biology have revealed a high degree of functional plasticity that can be attributed to dynamic cell-to-cell interactions in concert with transcriptional and epigenetic reprogramming. Here, we discuss how new insights into the adaptive behavior of NK cells pave the way for next generation cell therapy based on guided differentiation and selective expansion of particularly cytotoxic NK cell subsets.
Collapse
Affiliation(s)
- Lisa L Liu
- Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Aline Pfefferle
- Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Vincent Oei Yi Sheng
- The KG Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Norway; Institute for Cancer Research, Oslo University Hospital, Norway
| | - Andreas T Björklund
- Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Vivien Béziat
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France; University Paris Descartes, Imagine Institute, Paris, France
| | - Jodie P Goodridge
- The KG Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Norway; Institute for Cancer Research, Oslo University Hospital, Norway
| | - Karl-Johan Malmberg
- Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; The KG Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Norway; Institute for Cancer Research, Oslo University Hospital, Norway.
| |
Collapse
|
56
|
Wang Y, Chen C, Dong F, Ma S, Xu J, Gong Y, Cheng H, Zhou Y, Cheng T, Hao S. NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions. SCIENCE CHINA-LIFE SCIENCES 2015; 58:1288-98. [DOI: 10.1007/s11427-015-4968-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/22/2015] [Accepted: 09/16/2015] [Indexed: 12/19/2022]
|
57
|
Rezvani K, Rouce RH. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Front Immunol 2015; 6:578. [PMID: 26635792 PMCID: PMC4648067 DOI: 10.3389/fimmu.2015.00578] [Citation(s) in RCA: 188] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2015] [Accepted: 10/29/2015] [Indexed: 12/17/2022] Open
Abstract
Natural killer (NK) cells are essential components of the innate immune system and play a critical role in host immunity against cancer. Recent progress in our understanding of NK cell immunobiology has paved the way for novel NK cell-based therapeutic strategies for the treatment of cancer. In this review, we will focus on recent advances in the field of NK cell immunotherapy, including augmentation of antibody-dependent cellular cytotoxicity, manipulation of receptor-mediated activation, and adoptive immunotherapy with ex vivo-expanded, chimeric antigen receptor (CAR)-engineered, or engager-modified NK cells. In contrast to T lymphocytes, donor NK cells do not attack non-hematopoietic tissues, suggesting that an NK-mediated antitumor effect can be achieved in the absence of graft-vs.-host disease. Despite reports of clinical efficacy, a number of factors limit the application of NK cell immunotherapy for the treatment of cancer, such as the failure of infused NK cells to expand and persist in vivo. Therefore, efforts to enhance the therapeutic benefit of NK cell-based immunotherapy by developing strategies to manipulate the NK cell product, host factors, and tumor targets are the subject of intense research. In the preclinical setting, genetic engineering of NK cells to express CARs to redirect their antitumor specificity has shown significant promise. Given the short lifespan and potent cytolytic function of mature NK cells, they are attractive candidate effector cells to express CARs for adoptive immunotherapies. Another innovative approach to redirect NK cytotoxicity towards tumor cells is to create either bispecific or trispecific antibodies, thus augmenting cytotoxicity against tumor-associated antigens. These are exciting times for the study of NK cells; with recent advances in the field of NK cell biology and translational research, it is likely that NK cell immunotherapy will move to the forefront of cancer immunotherapy over the next few years.
Collapse
Affiliation(s)
- Katayoun Rezvani
- Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA
| | - Rayne H Rouce
- Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine , Houston, TX , USA ; Center for Cell and Gene Therapy, Baylor College of Medicine Houston Methodist Hospital and Texas Children's Hospital , Houston, TX , USA
| |
Collapse
|